Microbiological, Histological, Immunological, and Toxin Response to Antibiotic Treatment in the Mouse Model of Mycobacterium ulcerans Disease

PLoS Neglected Tropical Diseases

Volumn 7, Issue 3, 2013, Pages

  Sarfo, Fred Stephen ^a,c   Converse, Paul J ^b   Almeida, Deepak V ^b   Zhang, Jihui ^c   Robinson, Clive ^c   Wansbrough Jones, Mark ^c   Grosset, Jacques H ^b  

^a KOMFO ANOKYE TEACHING HOSPITAL   (Ghana)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 15; INTERLEUKIN 17; RIFAMPICIN; STREPTOMYCIN; VIRULENCE FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; BURULI ULCER; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOTOXICITY; DISEASE ASSOCIATION; HISTOLOGY; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOLOGY; MASS SPECTROMETRY; MICROBIOLOGY; MOUSE; MYCOBACTERIUM ULCERANS; NONHUMAN; SWELLING;

EID: 84875998264     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002101     Document Type: Article

References (42)

1. Converse PJ, Nuermberger EL, Almeida DV, Grosset JH, (2011) Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife? Future Microbiology 6: 1185-1198.
2. Amofah G, Bonsu F, Tetteh C, Okrah J, Asamoa K, et al. (2002) Buruli ulcer in Ghana: results of a national case search. Emerg Infect Dis 8: 167-170.
3. Sopoh GE, Johnson RC, Chauty A, Dossou AD, Aguiar J, et al. (2007) Buruli ulcer surveillance, Benin, 2003-2005. Emerg Infect Dis 13: 1374-1376.
4. Dega H, Bentoucha A, Robert J, Jarlier V, Grosset J, (2002) Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice. Antimicrob Agents Chemother 46: 3193-3196.
5. George KM, Chatterjee D, Gunawardana G, Welty D, Hayman J, et al. (1999) Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 283: 854-857.
6. Krieg RE, Hockmeyer WT, Connor DH, (1974) Toxin of Mycobacterium ulcerans. Production and effects in guinea pig skin. Arch Dermatol 110: 783-788.
7. Read JK, Heggie CM, Meyers WM, Connor DH, (1974) Cytotoxic activity of Mycobacterium ulcerans. Infect Immun 9: 1114-1122.
8. Walsh DS, Portaels F, Meyers WM, (2011) Buruli ulcer: Advances in understanding Mycobacterium ulcerans infection. Dermatol Clin 29: 1-8.
9. Silva MT, Portaels F, Pedrosa J, (2009) Pathogenetic mechanisms of the intracellular parasite Mycobacterium ulcerans leading to Buruli ulcer. Lancet Infect Dis 9: 699-710.
10. Ruf M-T, Sopoh GE, Brun LV, Dossou AD, Barogui YT, et al. (2011) Histopathological Changes and Clinical Responses of Buruli Ulcer Plaque Lesions during Chemotherapy: A Role for Surgical Removal of Necrotic Tissue? PLoS Negl Trop Dis 5: e1334.
11. Almeida D, Converse PJ, Ahmad Z, Dooley KE, Nuermberger EL, et al. (2011) Activities of Rifampin, Rifapentine and Clarithromycin Alone and in Combination against Mycobacterium ulcerans Disease in Mice. PLoS Negl Trop Dis 5: e933.
12. Bentoucha A, Robert J, Dega H, Lounis N, Jarlier V, et al. (2001) Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother 45: 3109-3112.
13. Lefrancois S, Robert J, Chauffour A, Ji B, Jarlier V, (2007) Curing Mycobacterium ulcerans infection in mice with a combination of rifampin-streptomycin or rifampin-amikacin. Antimicrob Agents Chemother 51: 645-650.
14. Pettit JHS, Marchette NJ, Rees RJW, (1966) Mycobacterium ulcerans infection. Clinical and bacteriological study of the first cases recognized in South East Asia. British Journal of Dermatology 78: 187-197.
15. Converse PJ, Almeida DV, Nuermberger EL, Grosset JH, (2011) BCG-Mediated Protection against Mycobacterium ulcerans Infection in the Mouse. PLoS Neglected Tropical Diseases 5: e985.
16. Zhang T, Li S-Y, Converse PJ, Almeida DV, Grosset JH, et al. (2011) Using Bioluminescence To Monitor Treatment Response in Real Time in Mice with Mycobacterium ulcerans Infection. Antimicrob Agents Chemother 55: 56-61.
17. Shepard CC, (1967) A kinetic method for the study of the activity of drugs against Mycobacterium leprae. Int J Lepr 35: 429-436.
18. Dega H, Robert J, Bonnafous P, Jarlier V, Grosset J, (2000) Activities of several antimicrobials against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother 44: 2367-2372.
19. Mve-Obiang A, Lee RE, Portaels F, Small PL, (2003) Heterogeneity of mycolactones produced by clinical isolates of Mycobacterium ulcerans: implications for virulence. Infect Immun 71: 774-783.
20. Marsollier L, Brodin P, Jackson M, Kordulakova J, Tafelmeyer P, et al. (2007) Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis. PLoS Pathog 3: e62.
21. Sarfo FS, Phillips RO, Rangers B, Mahrous EA, Lee RE, et al. (2010) Detection of Mycolactone A/B in Mycobacterium ulcerans-Infected Human Tissue. PLoS Negl Trop Dis 4: e577.
22. Schütte D, Um-Boock A, Mensah-Quainoo E, Itin P, Schmid P, et al. (2007) Development of highly organized lymphoid structures in Buruli Ulcer lesions after treatment with rifampicin and streptomycin. PLoS Neglected Tropical Diseases 1: e2.
23. Schütte D, UmBoock A, Pluschke G, (2009) Phagocytosis of Mycobacterium ulcerans in the course of rifampicin and streptomycin chemotherapy in Buruli ulcer lesions. British Journal of Dermatology 160: 273-283.
24. Martins TG, Gama JB, Fraga AG, Saraiva M, Silva MT, et al. (2012) Local and Regional Re-Establishment of Cellular Immunity during Curative Antibiotherapy of Murine Mycobacterium ulcerans Infection. PLoS ONE 7: e32740.
25. Ruf MT, Schutte D, Chauffour A, Jarlier V, Ji B, et al. (2012) Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model. Antimicrob Agents Chemother 56: 687-696.
26. Torrado E, Fraga AG, Castro AG, Stragier P, Meyers WM, et al. (2007) Evidence for an intramacrophage growth phase of Mycobacterium ulcerans. Infect Immun 75: 977-987.
27. Connor DH, Lunn HF, (1965) Mycobacterium ulcerans infection (with comments on pathogenesis). Int J Lepr 33: Suppl: 698-709.
28. Connor DH, Lunn HF, (1966) Buruli Ulceration: a clincopathologic study of 38 Ugandans with Mycobacterium ulcerans ulceration. Arch Path 81: 183-199.
29. Connor DH, Meyers WM, Krieg RE (1976) Infection by Mycobacterium ulcerans. In: Binford CH, Connor DH, editors. Pathology of Tropical and Extraordinary Diseases. Washington, D.C.: Armed Forces Institute of Pathology. pp. 226-235.
30. Ramakrishnan L, (1997) Images in clinical medicine. Mycobacterium marinum infection of the hand. N Engl J Med 337: 612.
31. Adusumilli S, Mve-Obiang A, Sparer T, Meyers W, Hayman J, et al. (2005) Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune response and cellular location of M. ulcerans in vitro and in vivo. Cellular Microbiology 7: 1295-1304.
32. En J, Goto M, Nakanaga K, Higashi M, Ishii N, et al. (2008) Mycolactone is responsible for the painlessness of Mycobacterium ulcerans infection (Buruli ulcer) in a murine study. Infect Immun 76: 2002-2007.
33. Goto M, Nakanaga K, Aung T, Hamada T, Yamada N, et al. (2006) Nerve Damage in Mycobacterium ulcerans-Infected Mice: Probable Cause of Painlessness in Buruli Ulcer. Am J Pathol 168: 805-811.
34. Oliveira MS, Fraga AG, Torrado E, Castro AG, Pereira JP, et al. (2005) Infection with Mycobacterium ulcerans Induces Persistent Inflammatory Responses in Mice. Infect Immun 73: 6299-6310.
35. Torrado E, Adusumilli S, Fraga AG, Small PLC, Castro AG, et al. (2007) Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection. Infect Immun 75: 3979-3988.
36. Peduzzi E, Groeper C, Schütte D, Zajac P, Rondini S, et al. (2007) Local activation of the innate immune system in Buruli ulcer lesions. J Invest Dermatol 127: 638-645.
37. Coutanceau E, Marsollier L, Brosch R, Perret E, Goossens P, et al. (2005) Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin. Cellular Microbiology 7: 1187-1196.
38. Martins TG, Trigo G, Fraga AG, Gama JB, Longatto-Filho A, et al. (2012) Corticosteroid-Induced Immunosuppression Ultimately Does Not Compromise the Efficacy of Antibiotherapy in Murine Mycobacterium ulcerans Infection. PLoS Negl Trop Dis 6: e1925.
39. Beissner M, Symank D, Phillips RO, Amoako YA, Awua-Boateng N-Y, et al. (2012) Detection of Viable Mycobacterium ulcerans in Clinical Samples by a Novel Combined 16S rRNA Reverse Transcriptase/IS2404 Real-Time qPCR Assay. PLoS Negl Trop Dis 6: e1756.
40. Fraga AG, Cruz A, Martins TG, Torrado E, Saraiva M, et al. (2011) Mycobacterium ulcerans Triggers T-Cell Immunity followed by Local and Regional but Not Systemic Immunosuppression. Infect Immun 79: 421-430.
41. Hong H, Coutanceau E, Leclerc M, Caleechurn L, Leadlay PF, et al. (2008) Mycolactone diffuses from Mycobacterium ulcerans-infected tissues and targets mononuclear cells in peripheral blood and lymphoid organs. PLoS Negl Trop Dis 2: e325.
42. Sarfo FS, Le Chevalier F, Aka NG, Phillips RO, Amoako Y, et al. (2011) Mycolactone Diffuses into the Peripheral Blood of Buruli Ulcer Patients- Implications for Diagnosis and Disease Monitoring. PLoS Negl Trop Dis 5: e1237.